Veterinary Medicines

Rispoval Pasteurella, lyofilisaat en suspendeervloeistof voor emulsie voor injectie voor runderen

Not authorised
  • Mannheimia haemolytica, serotype A1, strain NL 1009, capsular antigen
  • Mannheimia haemolytica, serotype A1, strain NL 1009, leucotoxoid
Download as PDF

Product identification

Medicine name:
Rispoval Pasteurella, lyofilisaat en suspendeervloeistof voor emulsie voor injectie voor runderen
Active substance:
  • Mannheimia haemolytica, serotype A1, strain NL 1009, capsular antigen
  • Mannheimia haemolytica, serotype A1, strain NL 1009, leucotoxoid
Target species:
  • Cattle
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Mannheimia haemolytica, serotype A1, strain NL 1009, capsular antigen
    200.00
    relative unit(s)
    /
    2.00
    millilitre(s)
  • Mannheimia haemolytica, serotype A1, strain NL 1009, leucotoxoid
    345.00
    relative unit(s)
    /
    2.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Cattle
      • Meat and offal
        no withdrawal period
  • Subcutaneous use
    • Cattle
      • Meat and offal
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI02AB04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Netherlands
Package description:
  • 5 doses of vaccine and solvent in glass vials (type I) with a rubber stopper and an aluminum cap (1 dose of 2 ml)
  • 25 doses of vaccine and solvent in glass vials (type I) with a rubber stopper and an aluminum cap (1 dose of 2 ml)
  • 1 dose of vaccine and solvent in glass vials (type I) with a rubber stopper and an aluminum cap (1 dose of 2 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
  • Zoetis B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 8661
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 1/11/2024
Download